Effects of Semaglutide Treatment on Psoriatic Lesions in Obese Patients with Type 2 Diabetes Mellitus: An Open-Label, Randomized Clinical Trial

Psoriasis is a chronic inflammatory skin disease with relapsing nature. Estimates are that approximately 2–3% of the world’s population suffers from this disease. More severe forms of psoriasis are conditions of high inflammation, which is confirmed by the clinical picture and numerous inflammatory...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jelena Petković-Dabić, Ivana Binić, Bojana Carić, Ljiljana Božić, Sanja Umičević-Šipka, Nataša Bednarčuk, Saša Dabić, Mirna Šitum, Snježana Popović-Pejičić, Miloš P. Stojiljković, Ranko Škrbić
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	MDPI AG 2025-01-01
Sarja:	Biomolecules
Aiheet:	psoriasis T2DM semaglutide PASI DLQI cytokine
Linkit:	https://www.mdpi.com/2218-273X/15/1/46
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!